Jazz Pharms Inc Drug Patent Portfolio

Jazz Pharms Inc owns 1 orange book drug protected by 3 US patents Given below is the list of Jazz Pharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11085043 Euglobulin-based method for determining the biological activity of defibrotide 22 Jun, 2032
Active
US11236328 Euglobulin-based method for determining the biological activity of defibrotide 22 Jun, 2032
Active
US11746348 Euglobulin-based method for determining the biological activity of defibrotide 22 Jun, 2032
Active


Given below is the list of recent legal activities going on the following drug patents of Jazz Pharms Inc.

Activity Date Patent Number
Patent litigations
Recordation of Patent eGrant 05 Sep, 2023 US11746348
Email Notification 05 Sep, 2023 US11746348
Mail Patent eGrant Notification 05 Sep, 2023 US11746348
Patent eGrant Notification 05 Sep, 2023 US11746348
Patent Issue Date Used in PTA Calculation 05 Sep, 2023 US11746348
Recordation of Patent Grant Mailed 05 Sep, 2023 US11746348
Email Notification 18 Aug, 2023 US11746348
Electronic Review 18 Aug, 2023 US11746348
Issue Notification Mailed 16 Aug, 2023 US11746348
Application Is Considered Ready for Issue 27 Jul, 2023 US11746348
Dispatch to FDC 27 Jul, 2023 US11746348
Filing Receipt - Corrected 17 Jul, 2023 US11746348
Electronic Review 17 Jul, 2023 US11746348
Email Notification 17 Jul, 2023 US11746348
Issue Fee Payment Verified 12 Jul, 2023 US11746348


Jazz Pharms Inc Drug Patents' Oppositions Filed in EPO

Jazz Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 29, 2018, by Aechter, Bernd. This opposition was filed on patent number EP12756826A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP12756826A Aug, 2018 Aechter, Bernd Patent maintained as amended


Jazz Pharms Inc's Family Patents

Jazz Pharms Inc drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 23.1% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Jazz Pharms Inc Drug List

Given below is the complete list of Jazz Pharms Inc's drugs and the patents protecting them.


1. Defitelio

Defitelio is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11085043 Euglobulin-based method for determining the biological activity of defibrotide 22 Jun, 2032
(7 years from now)
Active
US11236328 Euglobulin-based method for determining the biological activity of defibrotide 22 Jun, 2032
(7 years from now)
Active
US11746348 Euglobulin-based method for determining the biological activity of defibrotide 22 Jun, 2032
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Defitelio's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Jazz Pharms Inc News

Accusations of Delaying Release of Generic Sleep Disorder Drug Hurled at Jazz and Hikma to Keep Prices High

28 Aug, 2024

Japanese study finds that Jazz's Epidiolex is ineffective in treating treatment-resistant epilepsies despite increasing sales

23 Aug, 2024

Jazz Pharmaceuticals decision paves the way for a competitor's narcolepsy drug in the U.S., as reported by Yahoo Lifestyle Canada.

05 Mar, 2024

See More